BiotechTube
Formosa Pharmaceuticals

Formosa Pharmaceuticals

Taipei City, Taiwan· Est.

A clinical-stage biotech company developing ophthalmology and oncology therapies using its proprietary APNT® nanoparticle platform and ADC technology.

formosapharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

A clinical-stage biotech company developing ophthalmology and oncology therapies using its proprietary APNT® nanoparticle platform and ADC technology.

OphthalmologyOncologyAnti-infectives

Technology Platform

APNT® (Active Pharmaceutical Nanoparticle Technology) uses salts/sugars as milling media to reduce drug particle size to nanoscale, improving solubility, bioavailability, and absorption while maintaining API purity and enabling various dosage forms.

Opportunities

Growth opportunities include geographic expansion of APP13007 through additional licensing deals, extension of APNT® technology to inhalation and local injection formulations, and advancement of novel bispecific ADC TSY-310 in high-value oncology markets.

Risk Factors

Key risks include dependence on licensing partners for commercial success, competition in both ophthalmology steroid markets and crowded ADC oncology space, and execution risk in advancing novel bispecific ADC programs through clinical development.

Competitive Landscape

In ophthalmology, competes with established steroid eye drops but differentiates via APNT®'s improved bioavailability and safety profile; in oncology, enters competitive ADC market through biosimilar strategy and novel bispecific approach, leveraging manufacturing partnerships for cost advantage.

More companies in Taiwan →